You are not connected. The newsletter may include some user information, so they may not be displayed correctly.

AMS Newsletter | 29 September 2023

AMS Newsletter | 29 September 2023
AMS
www.menopause.org.au 29 Sep 2023
---
AMS Newsletter
---
Welcome to the AMS Newsletter for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.
 

In this edition

{tableofcontents|type:h3}
 

September 2023

Menopause Essentials Update | 4 November 2023, Perth WA

Join us for lunch followed by an update on the essentials of menopause management. This workshop is aimed at GPs, gynaecologists, endocrinologists and other health professionals who are seeking a comprehensive review of the current issues that face them in the diagnosis and management of menopausal symptoms.

Presentations will include case studies and there will be time for questions.

Topics include:

  • Menopause consultation: A structured approach to decision-making
  • Prescribing MHT: Evidence base, tips, tricks and practice pearls
  • Non-hormonal treatment for troublesome symptoms of menopause: what‚Äôs the evidence?¬†
  • MHT in difficult circumstances
Menopause Essentials Update

Download flyer here:  pdfMenopause Essentials Update Saturday 4 November 2023

AMS members: free 

AMS non-members: $100 (GST inc)

Register

Go to Trybooking at: www.trybooking.com/CLOZA

Continuing Education

RACGP 6 points

ACRRM 3 points

read more 

Updated AMS Information Sheet: Tibolone as menopausal hormone therapy

AMS Tibolone as menopausal hormone therapy

AMS is pleased to present an updated version of the Tibolone as menopausal hormone therapy with thanks to Dr Ashley Makepeace. Tibolone is a synthetic steroid hormone. Its metabolites have oestrogenic, progestogenic and androgenic properties. Indications are for the management of oestrogen deficiency symptoms and for the prevention of bone loss at the time of menopause.

Dr Christina Jang
Coordinator, AMS Information and Fact Sheets

IMS World Congress on Menopause in Melbourne 2024

IMS World Congress on Menopause in Melbourne 2024

Health Professionals - join AMS for Members-only content 

IMS Live 4 Sep 2023: The reverse of reproductive aging: ovarian recovery through autologous platelet-rich plasma
With the increase in health and life expectancy, the number of menopausal women has increased significantly. In parallel, there has been a reduction of birth rates influenced by women having their first maternity in an advanced age. Both trends have an impact on national demographics and impose a socioeconomic challenge for which there is no current solution. Women with symptomatic menopause and those with infertility/miscarriage may take advantage of standard therapies such as menopause hormone therapy (MHT) or in vitro fertilization, respectively...

IMS Live 11 Sep 2023: Associations between dietary patterns and an array of inflammation biomarkers and plasma lipid profile in postmenopausal women
Recently, Ilesanmi-Oyelere et al. [1] reported the results of a cross-sectional study that evaluated the association between four dietary patterns, nutrients and food intakes and an array of systemic inflammation biomarkers and lipid profile among 80 postmenopausal women from New Zealand. The authors used a food frequency questionnaire to collect nutrients and food intake. Four dietary patterns were identified by principal component analysis (PCA) and plasma samples collected for the measuring of inflammatory biomarkers and lipid profile. The authors found that there were negative correlations between intake of dietary fiber, soluble and insoluble non-starch polysaccharides (NSP), vitamin C and niacin and almost all the inflammatory markers for the whole group...

IMS Live 18 Sep 2023: Continuous transdermal nitroglycerin does not decrease hot flush frequency and severity in peri- and postmenopausal women: results of a Randomized Placebo Controlled Clinical Trial
There has been an increase in the use of non-hormonal options to treat hot flashes among many menopausal women, basically due to the potential risks of long-term systemic estrogen therapy. Physiologic studies have shown that nitric oxide is pivotal in mediating vasodilation related to hot flash. Hence, it can be suggested that non-hormonal medications that induce nitrate tolerance in the vasculature may offer therapeutic benefit for vasomotor symptoms. Bearing this in mind, recently, Huang et al. [1] carried out a randomized, double-blinded, placebo-controlled clinical trial that included peri- or postmenopausal women that reported 7 or more hot flashes per day, in order to determine if the uninterrupted administration of transdermal nitroglycerin (NTG, aimed to induce nitrate cross-tolerance) would decrease the frequency or severity of menopause-related hot flashes...

Cardiovascular Disease and Menopause - video
Dr Erin Michos discusses how the menopause transition influences cardiometabolic risk factors and the relationship between vasomotor symptoms and heart disease. She reviews that early onset of menopause in women before age 45 years is considered a risk factor.

Practice Pearl: Primary Ovarian Insufficiency
Dr Ekta Kapoor from the Mayo Clinic in Rochester, Minnesota, summarizes the clinical manifestations, diagnostic evaluation, and management of primary ovarian insufficiency.

IMS Newsletter Septembert 2023
AMS is an affiliate of IMS See latest available copy.

European Menopause and Andropause Society (EMAS) Newsletter
AMS is an affiliate of EMAS. See a copy of the August newsletter.


---
Australasian Menopause Society
---
Copyright © 2023

Australasian Menopause Society Ltd.

PO Box 280, Healesville, VIC 3777

Tel: +61 3 5962 6241 | Email: ams@menopause.org.au

FacebookLinkedInTwitterInstagram

Health Professionals join the AMS now

Contact us | Unsubscribe
---

Email built with AcyMailing